Nabriva Therapeutics plc
25-28 North Wall Quay,
IFSC, Dublin 1, Ireland
September 9, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Nabriva Therapeutics plc
Registration Statement on Form S-3
File No. 333-248530
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nabriva Therapeutics plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-248530), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on September 11, 2020, or as soon thereafter as practicable.
| Very truly yours, | |
|
| |
|
| |
| NABRIVA THERAPEUTICS PLC | |
|
| |
|
| |
| By: | /s/ Theodore Schroeder |
|
| Name: Theodore Schroeder |
|
| Title: Chief Executive Officer |
